What happened
FDA’s CDER describes initiatives intended to encourage manufacturing innovation and reliable production of high-quality drugs. The Emerging Technology Program offers early engagement and recommendations for companies developing advanced manufacturing technologies, including continuous manufacturing, 3D printing, process analytical technology, distributed manufacturing, and artificial intelligence. CDER is also developing the FRAME regulatory framework, prioritizing end-to-end continuous, distributed, point-of-care, and AI-enabled manufacturing. FDA established the Advanced Manufacturing Technologies Designation Program and provides FAQs and draft guidance on eligibility and participation. The page also outlines international regulatory collaboration, integrated facility evaluation and inspection, quality management maturity, and voluntary quality metrics reporting efforts.
Why it matters
For pharmaceutical manufacturers, the page identifies FDA pathways for early discussion of advanced technologies and broader efforts to align regulatory evaluation, inspections, and quality-system development. Engagement through ETP or AMTDP may help companies obtain FDA recommendations or understand program eligibility during technology development and implementation. The QMM and quality metrics sections may also matter to sites evaluating how they monitor quality systems and continuous improvement, while international initiatives support harmonized standards and coordinated inspection practices.
Key topics: FDA advanced manufacturing engagement programs, Regulatory framework for emerging manufacturing technologies, Quality management maturity and international collaboration